Letter to Congress Correcting False Claims About Bayh-Dale Act and § 1498 on Drug Price Controls

September 29, 2023

On September 28th, 2023, a letter was sent to the Senate Health, Education, Labor and Pensions Committee, the Chair and Ranking Member of the House Ways and Means Committee, and to Secretary Becerra correcting false claims that the federal government can use the Bayh-Dole Act or § 1498 to impose price controls on prescription drugs.

The letter is signed by 25 scholars, former judges, and former government officials, including Judge Paul Michel, Judge Randall Rader, Judge Kathleen O’Malley, Judge Susan Braden, the Honorable Andrei Iancu, the Honorable Walter Copan, and the Honorable Ronald Cass. It also includes leading scholars and patent and healthcare law experts, such as Jonathan Barnett, Richard Epstein, Emily Morris, Kristen Osenga, and Ted Sichelman, among many others.

Download the letter here: Letter to Congress – Bayh-Dole and 1498 Not Basis for Price Controls on Drug

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor

U.S. Universities: Engines of Economic Growth

November 13, 2025

By Sujai Shivakumar, Charles Wessner, Chris Borges, and Shruti Sharma Universities are among the United States’ most enduring sources of competitive advantage and a key pillar of the nation’s innovation system. Home to more than 35 of the world’s top 100 research universities, the United States owes many of its most

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

October 13, 2025

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and